In patients with T2D in a phase 2 clinical trial, retatrutide (0.5 to 12 mg) significantly reduced body weight and HbA1c levels compared to placebo and 1.5 mg dulaglutide
For the placebo arm, there were 20 recorded medications, 100% (14/14) of patients were treated with metformin, 14.3% (2/14) were on dapagliflozin, 7.1% (1/14) were treated with either gliclazide, Humulin I, Insulutard or Victoza
Patients often experience fewer dramatic blood sugar fluctuations, which can feel steadier and more sustainable than other diabetes medications
Those enrolled in supervised tirzepatide programs, such as the one in La Mirada, get help tracking symptoms while maintaining proper nutrition
2026 study of health records about GLP-1s and risk of substance use disorder Researchers studied the electronic health records of over 600,000 veterans with diabetes
In the long run, some studies suggest these drugs may contribute to muscle loss along with fat loss